Biomed Radio - Washington University School Of Medicine In St. Louis

Patients with HIV are not in immediate danger of death anymore. Instead, thanks to antiretroviral therapy, most relatively live normal lives for many years. However, the combination of HIV and the drugs used to treat it leads many HIV-positive patients to develop lipid problems, diabetes, obesity and cardiovascular disease. The search for treatments to fight those complications has led researchers at Washington University School of Medicine in St. Louis to a drug that improves insulin sensitivity and lowers inflammation in people with HIV. The researchers believe long-term use of the drug, called sitagliptin, may help combat the metabolic problems that affect people with the virus. RESEARCHERS AT WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS HAVE FOUND THAT A DIABETES DRUG APPEARS TO LOWER CARDIOVASCULAR RISK AND MORE EFFECTIVELY TREAT GLUCOSE PROBLEMS IN PEOPLE WITH HIV. JIM DRYDEN REPORTS… ALTHOUGH HIV IS NO LONGER RAPIDLY FATAL, PEOPLE INFECTED WITH THE VIRUS WHO TAKE ANTIRETROVIRAL THERAPY HAV